Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:5280445
Structure:
Synonyms:
"3′,4′,5,7-tetrahydroxyflavone"
2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-benzopyrone
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
23A002A4-B47B-46CD-848C-65042EACF3FF
3′,4′,5,7-Tetrahydroxyflavone
3',4',5,7-Tetrahydroxy-Flavone
3',4',5,7-Tetrahydroxyflavone
491-70-3
4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-
4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI)
4H-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-
4H-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-;
5,7,3',4'-Tetrahydroxyflavone
5-18-05-00296 (Beilstein Handbook Reference)
AC-1125
AC1NQX1A
ACon1_000223
AIDS-001406
AIDS001406
AKOS002140588
BB_NC-1244
BIDD:ER0122
BIDD:PXR0059
BPBio1_001011
BRD-K05236810-001-05-9
BRN 0292084
BSPBio_000919
C.I. 75590
C.I. Natural Yellow 2
C01514
C15H10O6
CAS-491-70-3
CCRIS 3790
CHEBI:15864
CHEMBL151
Cyanidenon 1470
D047311
Digitoflavone
EINECS 207-741-0
Flacitran
FLAVONE, 3',4',5,7-TETRAHYDROXY-
HMS1570N21
HMS2097N21
HMS2220C06
I06-0436
IN1269
L 9283
L9283_SIGMA
LMPK12110006
Lopac0_000660
LS-69039
Luteolin
Luteolin, 3',4',5,7-Tetrahydroxyflavone, Luteoline, Luteolol
Luteolin-Supplied by Selleck Chemicals
Luteoline
Luteolol
MEGxp0_000143
MLS000697655
MLS000860038
MLS002154043
MolPort-000-706-683
NCGC00016467-01
NCGC00016467-02
NCGC00016467-03
NCGC00016467-04
NCGC00016467-05
NCGC00016467-06
NCGC00016467-07
NCGC00142375-01
NCGC00142375-02
NCGC00142375-03
NCGC00179375-01
NCGC00179375-02
Oprea1_849964
Prestwick0_000870
Prestwick1_000870
Prestwick2_000870
Prestwick3_000870
Prestwick_122
S00110
S2320_Selleck
Salifazide
SMP2_000042
SMR000326896
SPBio_002840
ST024703
STK801923
TNP00073
Weld Lake
Yama kariyasu
ZINC18185774

Target

show target details
Uniprot ID:KPC1_LYTPI
Synonyms:
Protein kinase C
EC-Numbers:2.7.11.13
Organism:Lytechinus pictus
Painted sea urchin
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

12440735
Effects of polyphenolic anthrone derivatives, resistomycin and hypercin, on apoptosis in human megakaryoblastic leukemia CMK-7 cell line.. Yoshihito Shiono; Nobuyo Shiono; Shujiro Seo; Syuichi Oka; Yoshimitsu Yamazaki (2002) Zeitschrift fr Naturforschung. C, Journal of biosciences display abstract
A tetrahydroxyanthrone derivative, resistomycin, was isolated from the culture broth of Streptomyces sulphureus and a similar polyphenolic dianthraquinone, hypericin, was isolated from an extract of Hypericum perforatum L. as modulators for apoptosis. Resistomycin inhibited apoptosis induced by actinomycin D (AD) with or without acceleration by colcemid (CL) in human megakaryoblastic leukemia CMK-7 cells, IC50 for inhibition against AD-induced apoptosis was about 0.5 microM and IC50 for inhibition against AD plus CL-induced apoptosis was about 1 microM. CL alone induced weak apoptosis in cells, which was enhanced by resistomycin. Hypericin did not inhibit AD-induced apoptosis and slightly enhanced CL-induced apoptosis. Emodin, corresponding to 1 of 2 anthraquinone units in hypericin, did not show any effect on this apoptotic system. AD-induced apoptosis was inhibited by the antioxidative flavonoid, luteolin (IC50 45 microM), and a protein kinase C (PKC) inhibitor, staurosporine (IC50 1.5 microM), but these compounds did not affect the CL-induced apoptosis. Hypericin and resistomycin scavenged superoxide anion radicals at the same rate as luteolin. PKC in CMK-7 cells was inhibited by hypericin and luteolin, but not significantly inhibited by resistomycin. This result suggests that the inhibition of AD-induced apoptosis by resistomycin is at least partly correlated with its antioxidative activity, and that the enhancement of CL-induced apoptosis by this compound depends upon the lack of PKC inhibitory activity. Though the mechanism is not clear, the enhancement of the CL-induced apoptosis might be hindered by PKC inhibition in the case of hypericin and luteolin.